The objective of this study is to compare how accurately the Xpert MTB/RIF assay Ct value at diagnosis and the AI-based tuberculosis activity score predict the treatment outcome of rifampin-susceptible pulmonary tuberculosis patients. As a retrospective observational study, data from patients diagnosed with rifampin susceptible pulmonary tuberculosis through the Xpert MTB/RIF assay performed on sputum in 2019 at the participating institutions will be analyzed (up to 900 people).
Study Type
OBSERVATIONAL
Enrollment
900
The clinical characteristics at the time of diagnosis of rifampin-susceptible pulmonary tuberculosis patients, the Xpert MTB/RIF assay Ct value, the tuberculosis activity score based on AI of the chest image, and treatment results will be collected retrospectively through medical records.
Seoul National University
Seoul, South Korea
Negative culture conversion until 8 weeks after initiation of treatment
Conversion from positive tuberculosis culture to negative tuberculosis culture
Time frame: Within 8 weeks of initiating treatment
Time to negative culture conversion
Time (days) to conversion from positive tuberculosis culture to negative tuberculosis culture
Time frame: Within 6 months of initiating treatment
Treatment outcome including 1) Cure 2) Treatment completion 3) Treatment failure 4) Death 5) Loss of follow-up 6) Unknown
1. Cure: confirmed negative culture conversion plus negative culture results from at least one sputum on the month of treatment completion 2. Treatment completion: confirmed negative culture conversion at least once during treatment 3. Treatment failure: positive culture results after 4 months of treatment 4. Death: death during treatment 5. Loss of follow-up: loss of follow-up during treatment 6. Unknown
Time frame: Within 2 years of initiating treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.